Saltar al contenido

A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs — October 02, 2026

2 de octubre de 2026 · 10 min

Notas del episodio

A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data.

In this episode
  1. Higher GLP-1 costs lead to lower adherence | EurekAlert! — EurekAlert!

    Higher GLP-1 costs lead to lower adherence | EurekAlert! News Release 30-Sep-2026 # Higher GLP-1 costs lead to lower adherence Patients significantly less likely to use the weight loss medication when monthly costs exceed $75 University of Georgia Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the…

  2. Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com — Margaret O'Hara [email protected]

    Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com # Ozempic driving massive increase in New Mexico Medicaid prescription drug spending Follow Margaret O'Hara - By Margaret O'Hara [email protected] #### Margaret O'Hara Health Care Accountability Reporter - Author email ([email protected]) - Sep 29, 2026…

  3. Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace — BioSpace

    Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace # Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic…

  4. Novel amylin drug confers 10% weight loss, well tolerated — Dorothy Brooks

    # Novel amylin drug confers 10% weight loss, well tolerated Author: Erik Swain Published: 2026-09-30T00:00:00 Source: healio.com (healio.com) Language: en ## Story Novel amylin drug confers 10% weight loss, well tolerated By Erik Swain Fact checked by Richard Smith # Novel amylin drug confers 10% weight loss with adverse events comparable to placebo September 30, 2026 5 min read By…

  5. People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 — Annika Kim Constantino

    # People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 Author: NOVO NORDISK INC. Published: 2026-09-30T09:45:00+00:00 Source: prnewswire.com (prnewswire.com) Language: en ## Story People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

Todos los episodios de GLP-1 Daily: Ozempic & Wegovy News

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.